Ripretinib domestic launch time

Ripretinib is a switch-controlled TKI approved for the treatment of advanced gastrointestinal stromal tumor GIST after treatment with three or more TKIs (including imatinib). In March 2021, the original drug of Ripetinib was approved by the State Food and Drug Administration and launched in the country. The trade name is Qingle, and it has been approved by the Medical Insurance Bureau to enter the scope of Class B medical insurance.

Ripetinibis a switch-controlled tyrosine kinase inhibitor that broadly inhibits KIT and PDGFRα mutant kinases by using the dual action mechanism of regulating the kinase switch pocket and activation loop. Repetinibinhibits major and minor KIT mutations in exons 9, 11, 13, 14, 17 and 18, as well as the major exon 17 D816V mutation associated with GIST. Repetinib also inhibits primary PDGFRα mutations in exons 12, 14 and 18, including the exon 18 D842V mutation, involved in a subset of GISTs.

The original drug Ripetinib that has entered the medical insurance is currently only available for reimbursement to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.